Eligibility of CFTR modulators for the adult-diagnosed cystic fibrosis population

J Cyst Fibros. 2020 Sep;19(5):840-841. doi: 10.1016/j.jcf.2020.04.018. Epub 2020 Jun 3.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age Factors
  • Aminophenols / therapeutic use*
  • Benzodioxoles / therapeutic use*
  • Chloride Channel Agonists / therapeutic use*
  • Cystic Fibrosis / diagnosis
  • Cystic Fibrosis / drug therapy*
  • Drug Combinations
  • Humans
  • Indoles / therapeutic use*
  • Patient Selection*
  • Pyrazoles / therapeutic use*
  • Pyridines / therapeutic use*
  • Quinolines / therapeutic use*

Substances

  • Aminophenols
  • Benzodioxoles
  • Chloride Channel Agonists
  • Drug Combinations
  • Indoles
  • Pyrazoles
  • Pyridines
  • Quinolines
  • elexacaftor, ivacaftor, tezacaftor drug combination